What is Exact Imaging?
Exact Imaging specializes in the development of high-resolution micro-ultrasound systems, specifically engineered to enhance the precision of prostate cancer detection. Its flagship platform, ExactVu, provides urologists with real-time, high-fidelity imaging capabilities that facilitate more accurate clinical decision-making. By bridging the gap between traditional ultrasound and more invasive diagnostic procedures, the company has established a robust intellectual property portfolio that serves a growing global customer base. The firm operates at the intersection of medical device innovation and oncology, positioning its technology as an essential tool for early-stage cancer screening and diagnostic accuracy.
How much funding has Exact Imaging raised?
Exact Imaging has raised a total of $37.2M across 4 funding rounds:
Series B
$6M
Series C
$16.1M
Other Financing Round
$5.1M
Other Financing Round
$10M
Series B (2014): $6M with participation from Veddis and iGan Partners
Series C (2017): $16.1M led by Lumira Capital, iGan Partners, Vesalius Biocapital Partners, and PMV
Other Financing Round (2021): $5.1M supported by Export Development Canada and BDC
Other Financing Round (2026): $10M featuring iGan Partners
Key Investors in Exact Imaging
iGan Partners
iGan Partners is one of Canada's largest healthcare-focused venture capital firms, investing across North America to commercialize and scale innovative healthcare solutions.
Lumira Capital
Lumira Capital is a prominent life sciences venture capital firm that focuses on building high-growth companies in the healthcare and biotechnology sectors.
Vesalius Biocapital Partners
Vesalius Biocapital Partners is a specialized venture capital firm investing in innovative life science companies, with a particular focus on therapeutics, medical devices, and diagnostics.
What's next for Exact Imaging?
With the successful closure of this major strategic investment, Exact Imaging is well-positioned to accelerate its commercial expansion and deepen its penetration into international healthcare markets. The company is expected to leverage these resources to enhance its R&D pipeline, potentially expanding the application of its micro-ultrasound technology beyond urology into broader diagnostic fields. As the firm transitions into this next phase of enterprise-level growth, the focus will likely shift toward scaling manufacturing capabilities and strengthening its clinical evidence base to ensure widespread adoption of the ExactVu platform as a standard of care.
See full Exact Imaging company page
